DE60327428D1 - Hif hydroxylase-inhibitoren zur anämiebehandlung - Google Patents
Hif hydroxylase-inhibitoren zur anämiebehandlungInfo
- Publication number
- DE60327428D1 DE60327428D1 DE60327428T DE60327428T DE60327428D1 DE 60327428 D1 DE60327428 D1 DE 60327428D1 DE 60327428 T DE60327428 T DE 60327428T DE 60327428 T DE60327428 T DE 60327428T DE 60327428 D1 DE60327428 D1 DE 60327428D1
- Authority
- DE
- Germany
- Prior art keywords
- hydroxylase inhibitors
- hif hydroxylase
- anemia treatment
- treatment
- activity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0206711.4A GB0206711D0 (en) | 2002-03-21 | 2002-03-21 | HIF Inhibitor |
PCT/GB2003/001239 WO2003080566A2 (en) | 2002-03-21 | 2003-03-21 | Hif hydroxylase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
DE60327428D1 true DE60327428D1 (de) | 2009-06-10 |
Family
ID=9933457
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60327428T Expired - Lifetime DE60327428D1 (de) | 2002-03-21 | 2003-03-21 | Hif hydroxylase-inhibitoren zur anämiebehandlung |
Country Status (13)
Country | Link |
---|---|
US (2) | US20050227948A1 (de) |
EP (2) | EP2065366A3 (de) |
JP (1) | JP2005520859A (de) |
CN (6) | CN101199502A (de) |
AT (1) | ATE430127T1 (de) |
AU (2) | AU2003216857B2 (de) |
CA (1) | CA2479881A1 (de) |
DE (1) | DE60327428D1 (de) |
ES (1) | ES2322992T3 (de) |
GB (1) | GB0206711D0 (de) |
MX (1) | MXPA04009155A (de) |
PL (1) | PL205110B1 (de) |
WO (1) | WO2003080566A2 (de) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8124582B2 (en) | 2002-12-06 | 2012-02-28 | Fibrogen, Inc. | Treatment of diabetes |
US7618940B2 (en) | 2002-12-06 | 2009-11-17 | Fibrogen, Inc. | Fat regulation |
US20050170019A1 (en) * | 2003-10-22 | 2005-08-04 | Fred Hutchinson Cancer Research Center | Methods, compositions and devices for inducing stasis in cells |
US20050136125A1 (en) * | 2003-10-22 | 2005-06-23 | Roth Mark B. | Methods, compositions and devices for inducing stasis in cells, tissues, organs, and organisms |
AU2004285477A1 (en) * | 2003-10-22 | 2005-05-12 | Fred Hutchinson Cancer Research Center | Methods, compositions and devices for inducing stasis in tissues and organs |
JP2007530522A (ja) * | 2004-03-26 | 2007-11-01 | アイシス・イノベーション・リミテッド | アッセイ |
ES2686777T3 (es) * | 2004-11-24 | 2018-10-19 | Lifescan, Inc. | Composiciones y métodos para crear un ambiente vascularizado para trasplante celular |
CA2605631A1 (en) * | 2005-04-20 | 2006-10-26 | Fred Hutchinson Cancer Research Center | Methods, compositions and articles of manufacture for enhancing survivability of cells, tissues, organs, and organisms |
DE102005019712A1 (de) * | 2005-04-28 | 2006-11-09 | Bayer Healthcare Ag | Dipyridyl-dihydropyrazolone und ihre Verwendung |
GB0519605D0 (en) | 2005-09-26 | 2005-11-02 | Isis Innovation | Assay |
BRPI0707302B8 (pt) | 2006-01-27 | 2021-05-25 | Fibrogen Inc | compostos de cianoisoquinolina que atuam no dano tecidual associado com isquemia, hipóxia e anemia, bem como composição farmacêutica que os compreende |
RU2461557C2 (ru) | 2006-04-04 | 2012-09-20 | Файброджен, Инк. | Соединения пирроло- и тиазолопиридина (варианты) и фармацевтическая композиция на их основе |
WO2008130527A1 (en) * | 2007-04-18 | 2008-10-30 | Merck & Co., Inc. | Novel 1,8-naphthyridine compounds |
US20110039878A1 (en) * | 2007-11-02 | 2011-02-17 | Volkmar Guenzler-Pukall | Methods for reducing blood pressure |
WO2009073669A1 (en) | 2007-12-03 | 2009-06-11 | Fibrogen, Inc. | Isoxazolopyridine derivatives for use in the treatment of hif-mediated conditions |
US8952160B2 (en) | 2008-01-11 | 2015-02-10 | Fibrogen, Inc. | Isothiazole-pyridine derivatives as modulators of HIF (hypoxia inducible factor) activity |
US8324405B2 (en) | 2008-02-05 | 2012-12-04 | Fibrogen, Inc. | Chromene derivatives and use thereof as HIF hydroxylase activity inhibitors |
WO2009134847A1 (en) * | 2008-04-30 | 2009-11-05 | Smithkline Beecham Corporation | Prolyl hydroxylase inhibitors |
GB0809262D0 (en) | 2008-05-21 | 2008-06-25 | Isis Innovation | Assay |
CN102264740B (zh) | 2008-08-20 | 2014-10-15 | 菲布罗根有限公司 | 一种吡咯[1,2-b]哒嗪衍生物及其作为hif调节剂的用途 |
CN102272117B (zh) | 2008-11-14 | 2015-06-17 | 菲布罗根有限公司 | 作为hif羟化酶抑制剂的苯并噻喃衍生物 |
EP3936608A1 (de) | 2010-03-31 | 2022-01-12 | The Scripps Research Institute | Umprogrammierung von zellen |
WO2012106472A1 (en) | 2011-02-02 | 2012-08-09 | Fibrogen, Inc. | Naphthyridine derivatives as inhibitors of hypoxia inducible factor (hif) hydroxylase |
GB201102659D0 (en) | 2011-02-15 | 2011-03-30 | Isis Innovation | Assay |
GB201113101D0 (en) | 2011-07-28 | 2011-09-14 | Isis Innovation | Assay |
US9446031B2 (en) | 2012-01-18 | 2016-09-20 | National University Of Singapore | Compositions and methods for neovascularization |
WO2013134632A2 (en) * | 2012-03-09 | 2013-09-12 | Fibrogen, Inc. | Treatment for high cholesterol |
ES2694297T3 (es) | 2013-01-24 | 2018-12-19 | Fibrogen, Inc. | Formas cristalinas de ácido {[1-ciano-5-(4-clorofenoxi)-4-hidroxi-isoquinolina-3-carbonilo]-amino}-acético |
CA3009350A1 (en) * | 2016-01-05 | 2017-07-13 | The Trustees Of Columbia University In The City Of New York | Compositions and methods for regulating activity of inhibitor of dna binding-2 (id2) protein |
EP3638217A4 (de) * | 2017-06-15 | 2021-05-26 | The Trustees of Columbia University in the City of New York | Behandlung von neurodegeneration durch neuprogrammierung des stoffwechsels durch hemmung von phd |
WO2021216530A1 (en) | 2020-04-20 | 2021-10-28 | Akebia Therapeutics, Inc. | Treatment of viral infections, of organ injury, and of related conditions using a hif prolyl hydroxylase inhibitor or a hif-alpha stabilizer |
WO2022150623A1 (en) | 2021-01-08 | 2022-07-14 | Akebia Therapeutics, Inc. | Compounds and composition for the treatment of anemia |
TW202313072A (zh) | 2021-05-27 | 2023-04-01 | 美商凱立克斯生物製藥股份有限公司 | 檸檬酸鐵之兒科調配物 |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1620359A1 (de) | 1965-12-10 | 1969-12-18 | Norddeutsche Affinerie | Wachstumbeeinflussende Mittel |
AT279048B (de) | 1967-07-04 | 1970-02-25 | Pharmazeutische Fabrik Montavit Gmbh | Verfahren zur Herstellung neuer, löslicher und stabiler organischer Eisen(III)-Komplexverbindungen und Injektionslösungen davon |
FR6969M (de) | 1968-05-19 | 1969-05-19 | ||
US4273779A (en) * | 1976-12-23 | 1981-06-16 | Ciba-Geigy Corporation | Treating hypertension with substituted-5-amino-2-pyridinecarboxylic acids |
JPS5754151A (en) * | 1980-09-18 | 1982-03-31 | Takeda Chem Ind Ltd | Physiologically active substance b-52653 and its preparation |
JPS5899453A (ja) * | 1981-12-10 | 1983-06-13 | Mitsubishi Chem Ind Ltd | オリゴペプチド |
US4446038A (en) * | 1982-09-27 | 1984-05-01 | Texaco, Inc. | Citric imide acid compositions and lubricants containing the same |
US4551279A (en) * | 1984-01-09 | 1985-11-05 | G. D. Searle & Co. | Protease inhibitors |
JPS6197229A (ja) | 1984-10-18 | 1986-05-15 | Chugai Pharmaceut Co Ltd | 安定なエリトロポエチン製剤 |
EP0185225B1 (de) | 1984-12-17 | 1990-01-03 | American Cyanamid Company | Platinkomplexe von aliphatischen Tricarbonsäuren |
JPS61218522A (ja) | 1985-03-22 | 1986-09-29 | Sachimaru Senoo | 中性乃至弱アルカリ性で安定な水酸化鉄コロイド溶液 |
JPS61249993A (ja) | 1985-04-26 | 1986-11-07 | Tanabe Seiyaku Co Ltd | 新規有機白金錯体及びその製法 |
US4752602A (en) * | 1985-09-09 | 1988-06-21 | Board Of Regents, The University Of Texas System | Dipeptide alkyl esters and their uses |
DE3544338A1 (de) * | 1985-12-14 | 1987-06-19 | Hoechst Ag | Peptid-derivate mit inhibitorischer wirkung auf hydroxylierende enzyme, verfahren zu ihrer herstellung, diese enthaltende mittel und ihre verwendung |
FR2662359A1 (fr) | 1986-04-18 | 1991-11-29 | Flork Michel | Nouveaux peptides diuretiques et natriuretiques. |
CH673459A5 (de) | 1987-05-15 | 1990-03-15 | Eprova Ag | |
DE3818850A1 (de) * | 1988-06-03 | 1989-12-07 | Hoechst Ag | Oligopeptide mit zyklischen prolin-analogen aminosaeuren |
US5439930A (en) * | 1992-04-14 | 1995-08-08 | Russian-American Institute For New Drug Development | Biologically active n-acylprolydipeptides having antiamnestic, antihypoxic and anorexigenic effects |
RU2001588C1 (ru) | 1992-05-07 | 1993-10-30 | Феликс Семенович Ройтман | Сок с м котью |
JP3595352B2 (ja) | 1993-02-01 | 2004-12-02 | 株式会社サンギ | 抗腫瘍剤及び抗菌剤 |
DE4410453A1 (de) * | 1994-03-25 | 1995-09-28 | Hoechst Ag | Substituierte heterocyclische Carbonsäureamidester, ihre Herstellung und ihre Verwendung als Arzneimittel |
WO1997024145A1 (fr) * | 1995-12-28 | 1997-07-10 | Daiichi Radioisotope Laboratories, Ltd. | Medicaments d'aide au diagnostic |
RU2079307C1 (ru) | 1996-07-08 | 1997-05-20 | Михаил Александрович Каплан | Противоанемическое средство |
RU2111746C1 (ru) | 1996-07-31 | 1998-05-27 | Всероссийский научный центр по безопасности биологически активных веществ | Водный раствор, обладающий гепатопротекторным действием |
US5972894A (en) * | 1997-08-07 | 1999-10-26 | Cytran, Inc. | Peptides having potassium channel opener activity |
US6200974B1 (en) * | 1997-10-24 | 2001-03-13 | Zeneca Limited | Phenanthroline derivatives |
RU2141943C1 (ru) | 1998-11-27 | 1999-11-27 | Научно-исследовательский институт фармакологии при Волгоградской медицинской академии | Динатриевая соль n-ацетил-l-аспарагиновой кислоты, обладающая антидепрессантной и ноотропной активностью |
US6583299B1 (en) | 1999-05-20 | 2003-06-24 | G.D. Searle & Co. | α-amino-β-sulfonyl hydroxamic acid compounds |
WO2000074725A1 (en) * | 1999-06-04 | 2000-12-14 | Dana-Farber Cancer Institute, Inc. | Identification of compounds that modify transcriptional responses to hypoxia |
GB0013655D0 (en) | 2000-06-05 | 2000-07-26 | Prolifix Ltd | Therapeutic compounds |
JP4590157B2 (ja) * | 2001-03-21 | 2010-12-01 | アイシス イノヴェイション リミテッド | アッセイ、方法および手段 |
-
2002
- 2002-03-21 GB GBGB0206711.4A patent/GB0206711D0/en not_active Ceased
-
2003
- 2003-03-21 AU AU2003216857A patent/AU2003216857B2/en not_active Ceased
- 2003-03-21 CN CNA2007103081689A patent/CN101199502A/zh active Pending
- 2003-03-21 EP EP09001020A patent/EP2065366A3/de not_active Withdrawn
- 2003-03-21 JP JP2003578322A patent/JP2005520859A/ja active Pending
- 2003-03-21 EP EP03712396A patent/EP1485347B1/de not_active Revoked
- 2003-03-21 PL PL371515A patent/PL205110B1/pl not_active IP Right Cessation
- 2003-03-21 CN CNA2007103081674A patent/CN101199512A/zh active Pending
- 2003-03-21 AT AT03712396T patent/ATE430127T1/de not_active IP Right Cessation
- 2003-03-21 DE DE60327428T patent/DE60327428D1/de not_active Expired - Lifetime
- 2003-03-21 CN CNA2007103081693A patent/CN101199537A/zh active Pending
- 2003-03-21 CN CNA200710308166XA patent/CN101199501A/zh active Pending
- 2003-03-21 US US10/508,423 patent/US20050227948A1/en not_active Abandoned
- 2003-03-21 CN CNA2007103081706A patent/CN101199503A/zh active Pending
- 2003-03-21 CN CNB038109557A patent/CN100369891C/zh not_active Expired - Fee Related
- 2003-03-21 ES ES03712396T patent/ES2322992T3/es not_active Expired - Lifetime
- 2003-03-21 WO PCT/GB2003/001239 patent/WO2003080566A2/en active Application Filing
- 2003-03-21 MX MXPA04009155A patent/MXPA04009155A/es active IP Right Grant
- 2003-03-21 CA CA002479881A patent/CA2479881A1/en not_active Abandoned
-
2006
- 2006-09-11 US US11/518,157 patent/US7662854B2/en not_active Expired - Fee Related
-
2009
- 2009-06-03 AU AU2009202216A patent/AU2009202216A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
ATE430127T1 (de) | 2009-05-15 |
CA2479881A1 (en) | 2003-10-02 |
EP1485347B1 (de) | 2009-04-29 |
CN101199537A (zh) | 2008-06-18 |
PL371515A1 (en) | 2005-06-27 |
CN1653040A (zh) | 2005-08-10 |
JP2005520859A (ja) | 2005-07-14 |
US7662854B2 (en) | 2010-02-16 |
EP1485347A2 (de) | 2004-12-15 |
AU2009202216A1 (en) | 2009-06-25 |
WO2003080566A3 (en) | 2003-12-11 |
AU2003216857A1 (en) | 2003-10-08 |
US20070066576A1 (en) | 2007-03-22 |
US20050227948A1 (en) | 2005-10-13 |
EP2065366A2 (de) | 2009-06-03 |
EP2065366A3 (de) | 2009-09-02 |
CN101199512A (zh) | 2008-06-18 |
CN101199502A (zh) | 2008-06-18 |
CN101199503A (zh) | 2008-06-18 |
PL205110B1 (pl) | 2010-03-31 |
GB0206711D0 (en) | 2002-05-01 |
CN100369891C (zh) | 2008-02-20 |
CN101199501A (zh) | 2008-06-18 |
ES2322992T3 (es) | 2009-07-03 |
MXPA04009155A (es) | 2004-11-26 |
WO2003080566A2 (en) | 2003-10-02 |
AU2003216857B2 (en) | 2009-06-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60327428D1 (de) | Hif hydroxylase-inhibitoren zur anämiebehandlung | |
ZA200706010B (en) | 3-aryl-3-hydroxy-2-amino-propionic acid amides, 3-hetero-ayryl-3-hydroxy-2-amino-propionic acid amides and related compounds having analgesic and/or immunostimulant activity | |
HK1113056A1 (en) | Nicotinamide derivates useful as p38 inhibitors | |
IS7857A (is) | Setnar pýrróló-pýrasól afleiður sem kínasa hindrar | |
ATE410430T1 (de) | 2,3-dihydro-6-nitroimidazoä2,1- büoxazolverbindungen zur behandlung von tuberkulose | |
EP1596854A4 (de) | Behandlung von erkrankungen im zusammenhang mit verringerter stickoxid-bioverfügbarkeit, einschliesslich erhöhte arginase | |
FR12C0008I2 (fr) | Compositions et methodes permettant de stabiliser la transthyretine et d'inhiber un mauvais repliement de la transthyretine | |
EE05417B1 (et) | Epotilooni analoogide ja kemoterapeutikumide kombinatsiooni kasutamine teraapias | |
CY1110742T1 (el) | Αναστολεις ινδαζολης, βενζισοξαζολης, και βενζισοθειαζολης | |
IL174210A0 (en) | 1,4 disubstituted isoquinilone derivatives as raf-kinase inhibitors useful for the treatment of proliferative diseases | |
DE60332163D1 (de) | Zusammensetzung zur hautaufhellung | |
SE0203752D0 (sv) | New compounds | |
MY140031A (en) | Carbonyl compounds | |
DE60231804D1 (de) | Verwendung von hepcidin zur herstellung eines arzneimittels zur behandlung von eisenhomöostase störungen | |
ATE550013T1 (de) | Zink-konservierungszusammensetzung und anwendungsverfahren | |
ATE464396T1 (de) | Mikrosatellitenmarker in form von mononukleotidwiederholungen zur detektion von mikrosatelliteninstabilität | |
WO2006034296A3 (en) | Amino-containing compounds which inhibit memapsin 2 beta-secretase activity and methods of use thereof | |
EA200601699A1 (ru) | Замещённые фенокси- и фенилтиопроизводные для лечения пролиферативных нарушений | |
ATE555674T1 (de) | Zusammensetzung mit der reduzierten form von coenzym q10 und carotenoid-verbindung | |
MXPA05013251A (es) | Composiciones para estado de oxigeno mejorado en animales de compania. | |
DE602006003094D1 (de) | 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydrochinolin-derivate zur behandlung von unfruchtbarkeit | |
NO20053903D0 (no) | Nukleotidlipidesterderivater. | |
ATE519380T1 (de) | Unterstützung der kognitiven funktion | |
RS20060195A (en) | Imidazopyridine-derivatives as inducible no-synthase inhibitors | |
DE602004022423D1 (de) | Hemmung der s6-kinase-aktivität zur behandlung von insulinresistenz |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8363 | Opposition against the patent |